Cargando…

Beta-blockers in post-acute myocardial infarction patients: Drug prescription patterns from 2018 to Italy’s first wave of the COVID-19 pandemic

Background: Major guidelines recommend the initiation of a beta-blocker therapy after an acute myocardial infarction (AMI). We aimed to map the treatment pathway of beta-blockers for AMI survivors during the first wave of COVID-19 pandemic in Italy and to investigate predictors for treatment non-ini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olmastroni, Elena, Galimberti, Federica, Catapano, Alberico L., Tragni, Elena, Casula, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768333/ https://www.ncbi.nlm.nih.gov/pubmed/36569305 http://dx.doi.org/10.3389/fphar.2022.1040710

Ejemplares similares

Antibiotic Prescription in the Community-Dwelling Elderly Population in Lombardy, Italy: A Sub-Analysis of the EDU.RE.DRUG Study
por: Galimberti, Federica, et al.
Publicado: (2022)

Potentially Inappropriate Prescribing among Elderly Outpatients: Evaluation of Temporal Trends 2012–2018 in Piedmont, Italy
por: Galimberti, Federica, et al.
Publicado: (2022)

Impact of COVID-19 Pandemic on Adherence to Chronic Therapies: A Systematic Review
por: Olmastroni, Elena, et al.
Publicado: (2023)

A pragmatic controlled trial to improve the appropriate prescription of drugs in adult outpatients: design and rationale of the EDU.RE.DRUG study
por: Casula, Manuela, et al.
Publicado: (2020)

Evaluation of Factors Associated With Appropriate Drug Prescription and Effectiveness of Informative and Educational Interventions—The EDU.RE.DRUG Project
por: Galimberti, Federica, et al.
Publicado: (2022)

Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies
por: Casula, Manuela, et al.
Publicado: (2022)

Geographical Variation in Medication Prescriptions: A Multiregional Drug-Utilization Study
por: Russo, Veronica, et al.
Publicado: (2020)

The Effectiveness of Interventions to Evaluate and Reduce Healthcare Costs of Potentially Inappropriate Prescriptions among the Older Adults: A Systematic Review
por: Mucherino, Sara, et al.
Publicado: (2022)

Prevalence of the Prescription of Potentially Interacting Drugs
por: Tragni, Elena, et al.
Publicado: (2013)

Correction: Prevalence of the Prescription of Potentially Interacting Drugs
por: Tragni, Elena, et al.
Publicado: (2013)

Adherence to lipid-lowering treatment: the patient perspective
por: Casula, Manuela, et al.
Publicado: (2012)

The management of patients with chronic cardiovascular therapies in Lombardy region: The impact of the COVID-19 pandemic
por: Galimberti, F., et al.
Publicado: (2022)

The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group
por: Gazzotti, Marta, et al.
Publicado: (2022)

Corrigendum: The role of registers in increasing knowledge and improving management of children and adolescents affected by familial hypercholesterolemia: The LIPIGEN pediatric group
por: Gazzotti, Marta, et al.
Publicado: (2023)

Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations
por: Olmastroni, Elena, et al.
Publicado: (2022)

Adherence to Mediterranean Diet: A Population-Based Longitudinal Cohort Study
por: Mattavelli, Elisa, et al.
Publicado: (2023)

Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting
por: Tragni, Elena, et al.
Publicado: (2021)

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia
por: Olmastroni, Elena, et al.
Publicado: (2023)

Calcium-Channel Blockers: An Alternative Therapy to Beta-Blockers for Myocardial Infarction?
por: Hao, Kiyotaka, et al.
Publicado: (2023)

Adherence to the Mediterranean Diet: Impact of Geographical Location of the Observations
por: Mattavelli, Elisa, et al.
Publicado: (2022)

Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do Not Tell, Yet)
por: Casula, Manuela, et al.
Publicado: (2022)

Should We Be Using Upstream Beta-Blocker Therapy for Acute Myocardial Infarction?
por: Giannakopoulos, Georgios, et al.
Publicado: (2021)

Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it
por: Joo, Seung-Jae
Publicado: (2023)

Clinical Outcomes of Calcium-Channel Blocker vs Beta-Blocker: From the Korean Acute Myocardial Infarction Registry
por: Kim, Moo Hyun, et al.
Publicado: (2023)

Current patterns of beta‐blocker prescription in cardiac amyloidosis: an Italian nationwide survey
por: Tini, Giacomo, et al.
Publicado: (2021)

Beta-Blockers for the Secondary Prevention of Myocardial Infarction in People with Dementia: A Systematic Review
por: Lanham, David, et al.
Publicado: (2019)

Usefulness of universal beta-blocker therapy in patients after ST-elevation myocardial infarction
por: Ferreira, João André, et al.
Publicado: (2021)

Should beta‐blockers be continued as a treatment for myocardial infarction in the case of Kounis syndrome?
por: Amino, Mari, et al.
Publicado: (2021)

Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes
por: Ishak, Divan, et al.
Publicado: (2023)

The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

Beta-Blocker Use after Discharge in Patients with Acute Myocardial Infarction in the Contemporary Reperfusion Era
por: Hu, Mengjin, et al.
Publicado: (2022)

Atrioventricular block after reperfusion: A reflection on early beta-blocker therapy for acute myocardial infarction
por: Zhong, Yue, et al.
Publicado: (2017)

Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization
por: Sim, Hui Wen, et al.
Publicado: (2020)

Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database
por: Won, Hoyoun, et al.
Publicado: (2020)

One‐Year Landmark Analysis of the Effect of Beta‐Blocker Dose on Survival After Acute Myocardial Infarction
por: Goldberger, Jeffrey J., et al.
Publicado: (2021)

Adherence to beta‐blockers and long‐term risk of heart failure and mortality after a myocardial infarction
por: Desta, Liyew, et al.
Publicado: (2020)

HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role
por: Casula, Manuela, et al.
Publicado: (2021)

Beta-blockers in liver cirrhosis
por: Giannelli, Valerio, et al.
Publicado: (2014)

Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study)
por: Cicolari, Stefania, et al.
Publicado: (2021)

Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
por: Kezerashvili, Anna, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qits5e4tuooqu2p2aafmdc2kb3